232 related articles for article (PubMed ID: 29863497)
1. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Komura K; Yoshikawa Y; Shimamura T; Chakraborty G; Gerke TA; Hinohara K; Chadalavada K; Jeong SH; Armenia J; Du SY; Mazzu YZ; Taniguchi K; Ibuki N; Meyer CA; Nanjangud GJ; Inamoto T; Lee GM; Mucci LA; Azuma H; Sweeney CJ; Kantoff PW
J Clin Invest; 2018 Jul; 128(7):2979-2995. PubMed ID: 29863497
[TBL] [Abstract][Full Text] [Related]
2. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
3. Two Splice Variants of Y Chromosome-Located Lysine-Specific Demethylase 5D Have Distinct Function in Prostate Cancer Cell Line (DU-145).
Jangravi Z; Tabar MS; Mirzaei M; Parsamatin P; Vakilian H; Alikhani M; Shabani M; Haynes PA; Goodchild AK; Gourabi H; Baharvand H; Salekdeh GH
J Proteome Res; 2015 Sep; 14(9):3492-502. PubMed ID: 26215926
[TBL] [Abstract][Full Text] [Related]
4. Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma.
Ura A; Hayashi T; Komura K; Hosoya M; Takamochi K; Sato E; Saito S; Wakai S; Handa T; Saito T; Kato S; Suzuki K; Yao T;
J Pathol Clin Res; 2024 Jan; 10(1):e350. PubMed ID: 37974379
[TBL] [Abstract][Full Text] [Related]
5. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Yoshikawa Y; Stopsack KH; Wang XV; Chen YH; Mazzu YZ; Burton F; Chakraborty G; Rajanala SH; Hirani R; Nandakumar S; Lee GM; Frank D; Davicioni E; Liu G; Carducci MA; Azuma H; Kantoff PW; Sweeney CJ
Mol Oncol; 2022 Dec; 16(22):3994-4010. PubMed ID: 36087093
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Histone Lysine-Specific Demethylase 5D KDM5D) Isoform Expression in Prostate Cancer Cell Lines: a System Approach.
Jangravi Z; Najafi M; Shabani M
Iran Biomed J; 2016; 20(2):117-21. PubMed ID: 26728332
[TBL] [Abstract][Full Text] [Related]
7. KDM5D inhibits the transcriptional activation of FKBP4 by suppressing the expression of E2F1 in colorectal cancer in males.
Liu M; Gao N
Biochem Pharmacol; 2021 Dec; 194():114814. PubMed ID: 34688635
[TBL] [Abstract][Full Text] [Related]
8. Y disruption, autosomal hypomethylation and poor male lung cancer survival.
Willis-Owen SAG; Domingo-Sabugo C; Starren E; Liang L; Freidin MB; Arseneault M; Zhang Y; Lu SK; Popat S; Lim E; Nicholson AG; Riazalhosseini Y; Lathrop M; Cookson WOC; Moffatt MF
Sci Rep; 2021 Jun; 11(1):12453. PubMed ID: 34127738
[TBL] [Abstract][Full Text] [Related]
9. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
[TBL] [Abstract][Full Text] [Related]
10. Histone demethylase KDM5D upregulation drives sex differences in colon cancer.
Li J; Lan Z; Liao W; Horner JW; Xu X; Liu J; Yoshihama Y; Jiang S; Shim HS; Slotnik M; LaBella KA; Wu CJ; Dunner K; Hsu WH; Lee R; Khanduri I; Terranova C; Akdemir K; Chakravarti D; Shang X; Spring DJ; Wang YA; DePinho RA
Nature; 2023 Jul; 619(7970):632-639. PubMed ID: 37344599
[TBL] [Abstract][Full Text] [Related]
11. KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe.
Chen TM; Huang CM; Setiawan SA; Hsieh MS; Sheen CC; Yeh CT
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982384
[TBL] [Abstract][Full Text] [Related]
12. Increased Mars2 expression upon microRNA-4661-5p-mediated KDM5D downregulation is correlated with malignant degree of gastric cancer cells.
Gu J; Chu K
Cell Biol Int; 2021 Oct; 45(10):2118-2128. PubMed ID: 34273914
[TBL] [Abstract][Full Text] [Related]
13. KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male.
Shen X; Hu K; Cheng G; Xu L; Chen Z; Du P; Zhuang Z
J Cell Biochem; 2019 Aug; 120(8):12247-12258. PubMed ID: 30864186
[TBL] [Abstract][Full Text] [Related]
14. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
[TBL] [Abstract][Full Text] [Related]
15. Down-Regulation of a Male-Specific H3K4 Demethylase,
Meyfour A; Pahlavan S; Ansari H; Baharvand H; Salekdeh GH
J Proteome Res; 2019 Dec; 18(12):4277-4282. PubMed ID: 31560558
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
17. The Histone Demethylase KDM5D Drives Sex Differences in Colorectal Cancer.
Cancer Discov; 2023 Aug; 13(8):1761. PubMed ID: 37387591
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.
Metzger E; Imhof A; Patel D; Kahl P; Hoffmeyer K; Friedrichs N; Müller JM; Greschik H; Kirfel J; Ji S; Kunowska N; Beisenherz-Huss C; Günther T; Buettner R; Schüle R
Nature; 2010 Apr; 464(7289):792-6. PubMed ID: 20228790
[TBL] [Abstract][Full Text] [Related]
19. Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.
Mankan AK; Mankan N; de Las Heras B; Ramkissoon SH; Bodriagova O; Vidal L; Grande E; Saini KS
Adv Ther; 2024 Mar; 41(3):885-890. PubMed ID: 38198042
[TBL] [Abstract][Full Text] [Related]
20. JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.
Li N; Dhar SS; Chen TY; Kan PY; Wei Y; Kim JH; Chan CH; Lin HK; Hung MC; Lee MG
Cancer Res; 2016 Feb; 76(4):831-43. PubMed ID: 26747897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
